Signup/Login
If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Signup/Login
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
Monitor
IPO today
Legato Merger (LEGOU)
Foxwayne Enterprises Acquisition (FOXWU)
Gores Metropoulos II (GMIIU)
Tzp Strategies Acquisition (TZPSU)
Queen's Gambit Growth Capital (GMBTU)
Upcoming IPO
Roblox Corporation (RBLX)
Dream Finders Homes, Inc. (DFH)
Myt Netherlands (MYTE)
Primavera Capital Acquisition (PV.U)
Growth Capital Acquisition (GCACU)
Virtuoso Acquisition (VOSOU)
Patria Investments Limited (PAX)
Rlx Technology, Inc. (RLX)
European Sustainable Growth Acquisition (EUSGU)
Zim Integrated Shipping Services (ZIM)
Agrify (AGFY)
Shoals Technology Group, Inc. (SHLS)
Qualtrics International Inc. (XM)
Vinci Partners Investments Ltd. (VINP)
Ortho Clinical Diagnostics Holdings Plc (OCDX)
Priced IPO
Kuke Music Holding Limited (KUKE)
Playtika Holding Corp. (PLTK)
Driven Brands Holdings Inc. (DRVN)
Petco Health And Wellness Company, Inc. (WOOF)
Poshmark, Inc (POSH)
Affirm Holdings, Inc. (AFRM)
Motorsport Gaming US Llc (MSGM)
Qilian International Holding Group (QLI)
Cullinan Oncology, Llc (CGEM)
Gracell Biotechnologies Inc. (GRCL)
Medirom Healthcare Technologies (MRM)
Glucose Biosensor Systems Greater China (GBSG)
GBS (GBS)
908 Devices Inc. (MASS)
Virios Therapeutics (VIRI)
Midwest Holding (MDWT)
Scopus BioPharma (SCPS)
Upstart Holdings, Inc. (UPST)
BioAtla, Inc.. (BCAB)
Contextlogic Inc. (WISH)
More companies

Lixte Biotechnology Holdings (LIXT)

Sector - Healthcare

Price chart

Company News

IPO Profile

About company

They are a drug discovery company that uses biomarker technology to identify enzyme targets associated with serious common diseases and then designs novel compounds to attack those targets. Their product pipeline is primarily focused on inhibitors of protein phosphatases, used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers, and encompasses two major categories of compounds at various stages of pre-clinical and clinical development that they believe have broad therapeutic potential not only for cancer but also for other debilitating and life-threatening diseases. They have developed two series of pharmacologically active drugs, the LB-100 series and the LB-200 series. They believe that the mechanism by which compounds of the LB-100 series affect cancer cell growth is different from cancer agents currently approved for clinical use. Lead compounds from each series have activity against a broad spectrum of common and rarer human cancers in cell culture systems. In addition, compounds from both series have anti-cancer activity in animal models of glioblastoma multiforme, neuroblastoma, and medulloblastoma, all cancers of neural tissue. Lead compounds of the LB-100 series also have activity against melanoma, breast cancer and sarcoma in animal models and enhance the effectiveness of commonly used anti-cancer drugs in these model systems.
Industry
Pharmaceuticals
CEO CFO
John S. Kovach Robert N. Weingarten
Employees Founded
4 2005

Contacts

Address: 248 Route 25A, No. 2 East Setauket, NY 11733

Telephone: (631) 880-2907

Web page: http://www.lixte.com

IPO information

Expected Date 11/25/2020
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
-
Share prices ($)

Financial Data (last reporting year)

Market Cap (MM) $60.18
Revenues (MM) $0
Net Income (Loss) (MM) $-2.2

Voting

What do you think will happen with the LIXT share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
Shares Initial (MM) 1.5
Shares Revised (MM) 1.2
Expected offer amount (MM) $11
Realized offer amount(MM) $5.7
Underwriters
WestPark Capital
CO-Managers
-

Sector: Healthcare

Tweets about $LIXT

Tweets volume:

RT volume:

Timeframe:

Google Trends Stats